Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.50 |
| ▸ | MME | P08473 | 6/20 | 0.45 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.41 |
| ▸ | NMT2 | O60551 | 2/20 | 0.39 |
| ▸ | NMT1 | P30419 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456599 | 1.00 | TGFBR1 (0.50) | TGFBR1MMESLC15A2NMT2NMT1 | |
| SCHEMBL29556650 | 0.92 | TGFBR1 (0.57) | TGFBR1MMECA2CA1 | |
| SCHEMBL783083 | 0.92 | TGFBR1 (0.57) | TGFBR1MMECA2CA1 | |
| SCHEMBL783082 | 0.92 | TGFBR1 (0.57) | TGFBR1MMECA2CA1 | |
| SCHEMBL30945534 | 0.92 | ACE (0.45) | TGFBR1MMESLC15A2NMT2NMT1 | |
| SCHEMBL29372719 | 0.90 | TGFBR1 (0.42) | TGFBR1MMESLC15A2NMT2NMT1 | |
| SCHEMBL29051061 | 0.90 | MME (0.50) | TGFBR1MMESLC15A2CA2 | |
| SCHEMBL29702215 | 0.90 | ACE (0.50) | TGFBR1MMESLC15A2NMT2NMT1 | |
| SCHEMBL29051058 | 0.90 | MME (0.50) | TGFBR1MMESLC15A2CA2 | |
| SCHEMBL31707359 | 0.88 | TGFBR1 (0.47) | TGFBR1MMESLC15A2CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11761956-B2 | Nanopore biosensors for detection of proteins and nucleic acids | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-09-19 | — | — | US | claimed |
| US-20220154170-A1 | PROTEIN RESIDUE MAPPING USING A COMBINATION OF DEEP MUTATIONAL SCANNING AND PHAGE DISPLAY HIGH THROUGHPUT SEQUENCING | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-05-19 | — | — | US | claimed |
| EP-4731652-A1 | MULTI-SPECIFIC PROTEINACEOUS PRODRUG CONSTRUCTS | Aarhus Universitet (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-12551549-B2 | Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 ENV using multimerized ENV cores | FRED HUTCHINSON CANCER CENTER (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260041758-A1 | IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS | FRED HUTCHINSON CANCER CENTER (US) | 2026-02-12 | — | — | US | disclosed |
| US-20250346874-A1 | FUSION MOLECULES OF RATIONALLY-DESIGNED DNA-BINDING PROTEINS AND EFFECTOR DOMAINS | DUKE UNIVERSITY (US) | 2025-11-13 | — | — | US | disclosed |
| US-12422369-B2 | Immunosensor | PPB Technology Pty Ltd (AU) | 2025-09-23 | — | — | US | disclosed |
| EP-4617286-A2 | TREM2 ANTIGEN BINDING PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250224397-A1 | BORRELIA IMMUNOASSAYS AND MATERIALS THEREFOR | BIO RAD LABORATORIES INC (US) | 2025-07-10 | — | — | US | disclosed |
| US-12351839-B2 | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences | PRECISION BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025137325-A1 | IMMUNIZATION SCHEDULES TO ELICIT BROADLY-NEUTRALIZING ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) | FRED HUTCHINSON CANCER CENTER (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20220137047-A1 | BORRELIA IMMUNOASSAYS AND MATERIALS THEREFOR | BIO-RAD LABORATORIES, INC. | 2022-05-05 | — | — | US | disclosed |
| WO-2022086450-A1 | BACTERIAL MICROCOMPARTMENT VIRUS-LIKE PARTICLES | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2022-04-28 | — | — | WO | disclosed |
| CN-114341637-A | Immunosensor | 联邦科学工业研究组织 | 2022-04-12 | — | — | CN | disclosed |
| US-20220089657-A1 | MODIFIED PEPTIDES | SASINAPAS CO LTD (TH) | 2022-03-24 | — | — | US | disclosed |
| EP-3963324-A1 | IMMUNOSENSOR | Commonwealth Scientific and Industrial Research Organisation (AU) | 2022-03-09 | — | — | EP | disclosed |
| US-20220064623-A1 | ENDOLYSIN VARIANT | SASINAPAS CO., LTD. (TH) | 2022-03-03 | — | — | US | disclosed |
| EP-3661954-B1 | INTERLEUKIN-21 MUTEINS AND METHODS OF TREATMENT | AMGEN INC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551549-B2 | Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 ENV using multimerized ENV cores | CD4, VSIG8, FCGR3B | TGFBR1 3814/4885MME 2962/4885SLC15A2 3254/4885 |
| US-12422369-B2 | Immunosensor | KLK3, CD47, FCGR3B | TGFBR1 4249/4885MME 419/4885SLC15A2 3482/4885 |
| US-20260041758-A1 | IMMUNIZATION STRATEGIES TO MORE NATURALLY GUIDE THE MATURATION OF ANTIBODIES AGAINST HUMAN IMMMUNODEFICIENCY VIRUS (HIV) IN HIV-INFECTED SUBJECTS | CD4, IGSF11, ICOS | TGFBR1 1980/4885MME 1867/4885SLC15A2 805/4885 |
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | TGFBR1 2913/4885MME 965/4885SLC15A2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.